Drawing for AXCYNSIS AXCYNSIS THERAPEUTICS

USPTO serial 79407408

AXCYNSIS AXCYNSIS THERAPEUTICS

Reviewed by CopyMark Law Group

Reg. 7989011Status 700Registered
Filing date
Status date
Registration date
Oct 21, 2025
Examiner
DIEFENBACH, LINDSEY OLSON
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with AXCYNSIS AXCYNSIS THERAPEUTICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Joseph G. Chu

Joseph G. Chu JCIP155 N Lake Avenue, Suite 800Pasadena, CA 91101United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for use in oncology; pharmaceutical drugs being pharmaceutical preparations for use in the treatment of cancer; pharmaceutical products, namely, pharmaceutical preparations for suppressing tumors; biopharmaceutical preparations for the treatment of cancer; chemical preparations for pharmaceutical purposes, namely, for oncology.ACTIVE—
042Development of pharmaceuticals; pharmaceutical research and development; research and development for the pharmaceutical industry; biochemical research; biochemical research and analysis; biochemical research and development; biochemistry research services; bioinorganic chemistry research; biological research; biological research and analysis; biological research laboratory services; biological research services; biomedical research services; bioorganic chemistry research; biotechnological research; biotechnology research; chemical research; chemical research and analysis; chemical research and analysis services; chemical research laboratory services; chemical research services; technological research in the field of chemistry; chemistry research; clinical research in the field of antibody drug conjugates in oncology; consultancy in the field of pharmaceutical research; consultancy in the field of scientific research; consultancy in the field of technological research relating to pharmaceutical studies; consultancy relating to pharmaceutical research and development; consultancy relating to pharmaceutical research and development in the field of therapeutics; DNA analysis services for scientific research purposes; DNA screening for scientific research purposes; DNA sequencing being DNA analysis for medical research purposes; DNA sequencing technology research; gene therapy research; scientific research in the field of genetics and antibody drug conjugates; genetic testing for scientific research purposes; laboratory research in the fields of antibody drug conjugates in oncology and antibody drug conjugate development; laboratory research in the field of chemistry; laboratory research in the field of gene expression; laboratory research in the field of pharmaceuticals; laboratory research services relating to pharmaceuticals; medical research; medical research in the field of oncology; medical research laboratory services; medical research services; pharmaceutical research and development services; pharmaceutical research consultancy; pharmaceutical research services; chemical research services in the nature of preparation of scientific reports relating to chemical research; scientific research services in the nature of preparation of scientific reports relating to scientific research; product research; product research and development; providing information about medical and scientific research in the field of pharmaceuticals; providing information relating to scientific research in the fields of biochemistry and biotechnology; providing information and online information about scientific and technological services in the field of antibody drug conjugates in oncology and research and design relating thereto; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; provision of information relating to scientific research; provision of information relating to technological research in the field of antibody drug conjugates in oncology; research services, namely, scientific research; research and development in the field of biotechnology; research and development of new products; research and development of new products for others; research and development services for the pharmaceutical industry; research and development services in the field of antibodies; research and development services in the field of antibody technology; research and development services in the field of biochemistry; research and development services in the field of biotechnology; research and development services in the field of chemistry; research and development services in the field of pharmaceutical preparations; research in the field of biology; research in the field of biomedicine; research in the field of biotechnology; research in the field of chemistry; research on the subject of pharmaceuticals; research relating to biotechnology; research relating to chemistry; research relating to chemicals; research relating to medicine in the nature of medical research; research relating to molecular sciences; research relating to pharmaceuticals; research relating to science; research laboratory analysis services in the field of chemistry and bioconjugation; research to develop new products; scientific and industrial research in the field of antibody drug conjugates in oncology; scientific and technological services, namely, research and design in the field of antibody drug conjugates in oncology; scientific and technological services, namely, research and development in the field of antibody drug conjugates in oncology; scientific research; scientific research and analysis for scientific research purposes; scientific research and development; scientific research for medical purposes; scientific research for medical purposes in the area of cancerous diseases; scientific research in the field of biotechnology; scientific research into the development of new products; scientific research relating to biology; scientific research relating to chemistry; scientific research relating to chemical products; scientific research relating to genetics; scientific research services; technical research in the field of pharmaceutical studies; technical research projects and studies in the field of antibody drug conjugates in oncology.ACTIVE—
044Medical testing services in the nature of in vitro testing for medical diagnostic and treatment purposes and in vitro testing of pharmaceuticals; medical analysis services in the nature of in vitro analysis for medical diagnostic and treatment purposes and in vitro analysis in the nature of testing, inspection, or research of pharmaceuticals.ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 21, 2026FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Apr 30, 2026FICSFINAL DISPOSITION NOTICE SENT TO IB—
Apr 30, 2026FIMPFINAL DISPOSITION PROCESSED—
Apr 9, 2026OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Mar 23, 2026OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Mar 23, 2026OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Jan 21, 2026FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Oct 21, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Oct 21, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 2, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 2, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 27, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 29, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 28, 2025XAECEXAMINER'S AMENDMENT ENTERED—
Jul 28, 2025GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jul 28, 2025GNEAEXAMINERS AMENDMENT E-MAILED—
Jul 28, 2025CNEAEXAMINERS AMENDMENT -WRITTEN—
Jul 25, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 24, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 24, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 22, 2025RFNTREFUSAL PROCESSED BY IB—
Mar 4, 2025RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Mar 4, 2025RFRRREFUSAL PROCESSED BY MPU—
Jan 16, 2025RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jan 15, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 10, 2025DOCKASSIGNED TO EXAMINER—
Nov 8, 2024MAFRAPPLICATION FILING RECEIPT MAILED—
Nov 8, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 24, 2024REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance